0.01
—
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Bio-Gene Technology
Its shares trade on ASX under the ticker BGT.AX. It has been listed since 29 November 2017. In the fiscal year to 30 June 2025, it reported revenue of A$425,070 and a net loss of A$2.6m. At that date it held total assets of A$2.1m and shareholders' equity of A$1.6m.
Bio-Gene Technology Ltd. is a development company enabling the next generation of novel insecticides, addressing the problems of insecticide resistance and toxicity. The company is headquartered in Melbourne, Victoria. The company went IPO on 2017-11-29. The Company’s principal activity is to develop and commercialize insecticides/pesticides. Its platform technology is based on a naturally occurring class of chemicals known as beta-triketones, that seeks to address the global problems of insecticide resistance and toxicity. The firm's lead beta-triketone insecticide products include Flavocide and Qcide. Flavocide is a chemically synthesized product based on flavesone. Qcide is a natural oil product containing tasmanone as the active constituent. The oil is extracted from the leaves of the Gympie Messmate, by utilizing a steam distillation process. Its platform provides multiple solutions for insecticide manufacturers in applications across crop protection and storage, public health, animal health and consumer applications. The firm also aims to develop and commercialize a portfolio of targeted insect control and management solutions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Chemicals
- Listed since
- 29 Nov 2017
- Website
- bio-gene.com.au ↗
Leadership
Pay as last reported
- Mr. Soo Ding HuongNon-Executive Chairman of the Board
- Mr. Tim GroganChief Executive Officer, Managing Director
- Mr. Edmond TernChief Financial Officer, Joint Company Secretary
- Mr. Peter MayExecutive Director – Research and DevelopmentA$311,756
- Mr. Owen GroganDirector
- Mr. Andrew GuthrieNon-Executive DirectorA$54,000
- Mr. Christopher RamsayNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Bio-Gene Technology Ltd. develops beta-triketone insecticides addressing resistance and toxicity problems.
- Flavocide and Qcide are lead products based on flavesone and tasmanone respectively.
- The platform technology targets crop protection, public health, and animal health applications.
Weaknesses
- The company is a development stage firm with no commercialized products yet.
- IPO listing date 29 November 2017 shows limited market history.
- No mention of production capacity or manufacturing scale in the facts.
Opportunities
- Global demand for solutions to insecticide resistance and toxicity problems.
- Expansion into crop protection and storage applications using beta-triketone platform.
- Public health and animal health sectors offer new market segments for insecticides.
Threats
- Competition from established chemical pesticide manufacturers in Materials sector.
- Regulatory challenges for new insecticide approvals in global markets.
- Potential delays in commercializing beta-triketone insecticides due to development stages.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.